MBCOF (Marvel Biosciences) EBIT: $-0.78 Mil (TTM As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
33 GF Score
Price $0.12
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences EBIT?

Marvel Biosciences MBCOF +4.74% 33 EBIT is $-0.78 Mil as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Marvel Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2026 was $0.35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Marvel Biosciences's annualized ROC % for the quarter that ended in Apr. 2026 was 30.73%. Marvel Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Marvel Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -9.87%.

Marvel Biosciences  (OTCPK:MBCOF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Marvel Biosciences's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=0.344 * ( 1 - 0% )/( (1.678 + 0.561)/ 2 )
=0.344/1.1195
=30.73 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.232 - 1.356 - ( 0.199 - max(0, 3.034 - 0.232+0.199))
=1.678

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.343 - 1.316 - ( 0.316 - max(0, 1.877 - 0.343+0.316))
=0.561

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Marvel Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.388/( ( (0 + max(-1.338, 0)) + (0 + max(-1.306, 0)) )/ 2 )
=1.388/( ( 0 + 0 )/ 2 )
=1.388/0
= %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.019) - (1.356 + 0 + 0.00099999999999945)
=-1.338

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.01) - (1.316 + 0 + -2.2204460492503E-16)
=-1.306

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Marvel Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2026 )
=-0.782/7.926
=-9.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences EBIT Related Terms

Marvel Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences EBIT Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
EBIT
Get a 7-Day Free Trial -0.88 -1.97 -1.71 -1.12 -1.42

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.75 -0.20 -0.17 0.35

MBCOF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Marvel Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's EV-to-EBIT falls into.


MBCOF
33GF Score
Marvel Biosciences Corp MBCOF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.78 Mil mean?
Marvel Biosciences (MBCOF) has a EBIT of $-0.78 Mil as of Apr. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Marvel Biosciences.
Is Marvel Biosciences' EBIT too high?
Marvel Biosciences' current EBIT is $-0.78 Mil. Overall, Marvel Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' EBIT compare to VRTX and REGN?
Marvel Biosciences' EBIT of $-0.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Marvel Biosciences. Marvel Biosciences's current EBIT is $-0.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current EBIT of $-0.78 Mil. The current EBIT is $-0.78 Mil. Marvel Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current EBIT is $-0.78 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
33GF Score

Get the complete analysis for MBCOF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price